Cancer & SURVIVEiT News
Category Filter:
FDA approves Pluvicto for metastatic castration-resistant prostate cancer
FDA approves Pluvicto for metastatic castration-resistant prostate cancer On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a…
New Study from Foundation Medicine and Collaborators Further Demonstrates the Clinical Utility of Blood-Based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer
Results from the study assessing concordance of genomic alterations identified by liquid and tissue biopsy published in Clinical Cancer Research and to be presented at the American Society of Clinical Oncology 2021…
A Prostate Cancer Survivor’s Advice Around Cancer & Fear
We often talk about the fear that sets in after a cancer diagnosis. But the truth is, the fear of cancer exists even without a diagnosis. Anyone who has been…
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious…
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prosta
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.)…
A Prostate Cancer Surgeon (and Survivor) Reflects On What He’s Learned
Prostate cancer is the second most common type of cancer affecting men. In fact, the World Cancer Research Fund stated that 2018 saw 1.3 million new cases of prostate cancer.…
FDA approves Bayer’s Nubeqa® (darolutamide), for non-metastatic castration-resistant prostate cancer
FDA approves Bayer’s Nubeqa® (darolutamide), a new treatment for men with non-metastatic castration-resistant prostate cancer WHIPPANY, N.J., July 30, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an…
Rucaparib Granted Breakthrough Designation by FDA for mCRPC
Rucaparib Granted Breakthrough Designation by FDA for mCRPC Ariela Katz Published Online:5:05 PM, Tue October 2, 2018 Rucaparib (Rubraca) has received a breakthrough therapy designation from the FDA for single-agent use…